# Venous Leg Ulcer (VLU) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/venous-leg-ulcer-vlu

> 4 upcoming FDA catalysts in venous Leg Ulcer (VLU): escharex (ex-03, MDWD) on December 2026 (primary completion); escharex (ex-03, MDWD) on Dec 2026 to Mar 2027 (topline data readout); gel vehicle (MDWD) on August 2028 (primary completion); gel vehicle (MDWD) on Aug to Nov 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2026 | [Escharex (ex-03) primary completion](https://sec-api.dev/pdufa/escharex-ex-03) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT06568627 (A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568627)) |
| Dec 2026 to Mar 2027 | [Escharex (ex-03) topline data readout](https://sec-api.dev/pdufa/escharex-ex-03) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT06568627 (A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568627)) |
| August 2028 | [Gel vehicle primary completion](https://sec-api.dev/pdufa/gel-vehicle) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT07692178 (An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07692178)) |
| Aug to Nov 2028 | [Gel vehicle topline data readout](https://sec-api.dev/pdufa/gel-vehicle) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT07692178 (An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07692178)) |

## Drugs

- [Escharex (ex-03)](https://sec-api.dev/pdufa/escharex-ex-03) (MDWD)
- [Gel vehicle](https://sec-api.dev/pdufa/gel-vehicle) (MDWD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/venous-leg-ulcer-vlu.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Venous Leg Ulcer (VLU) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/venous-leg-ulcer-vlu

```bibtex
@misc{secapidev_indications_venous_leg_ulcer_vlu_20261116,
  title        = {Venous Leg Ulcer (VLU) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/venous-leg-ulcer-vlu}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_venous_leg_ulcer_vlu_20261116","title":"Venous Leg Ulcer (VLU) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/venous-leg-ulcer-vlu","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
